325.64
전일 마감가:
$325.28
열려 있는:
$327.53
하루 거래량:
595.92K
Relative Volume:
0.65
시가총액:
$42.46B
수익:
$2.35B
순이익/손실:
$-269.70M
주가수익비율:
-155.81
EPS:
-2.09
순현금흐름:
$-75.39M
1주 성능:
+0.88%
1개월 성능:
+4.00%
6개월 성능:
+18.18%
1년 성능:
+38.99%
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-21 | 개시 | Truist | Buy |
2025-03-31 | 개시 | Redburn Atlantic | Buy |
2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
2024-02-15 | 개시 | Wolfe Research | Peer Perform |
2023-12-08 | 개시 | Wells Fargo | Equal Weight |
2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2023-09-29 | 개시 | Raymond James | Outperform |
2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-04-26 | 개시 | SMBC Nikko | Neutral |
2023-03-21 | 개시 | Bernstein | Outperform |
2023-01-18 | 개시 | Canaccord Genuity | Buy |
2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-06-07 | 개시 | William Blair | Outperform |
2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-03-01 | 개시 | Citigroup | Buy |
2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
2021-02-12 | 재확인 | H.C. Wainwright | Buy |
2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2020-09-30 | 재개 | Berenberg | Hold |
2020-09-08 | 개시 | Citigroup | Buy |
2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-04-24 | 재개 | Evercore ISI | Outperform |
2020-03-19 | 개시 | Berenberg | Buy |
2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
2019-11-20 | 개시 | Oppenheimer | Outperform |
2019-11-13 | 개시 | BofA/Merrill | Buy |
2019-05-23 | 재개 | Goldman | Neutral |
2019-04-12 | 개시 | Evercore ISI | Outperform |
2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-01-23 | 개시 | UBS | Neutral |
2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
2018-08-13 | 재확인 | Stifel | Buy |
2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
2018-05-04 | 재확인 | Stifel | Hold |
2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
What drives Alnylam Pharmaceuticals Inc. stock priceMarket-crushing stock picks - Autocar Professional
Huntington's Disease Clinical, Companies, Therapeutic - openPR.com
What analysts say about Alnylam Pharmaceuticals Inc. stockTriple-digit growth rates - Autocar Professional
Alnylam Pharmaceuticals Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com
Alnylam Pharmaceuticals Surges to Top 277 Most Actively Traded Stocks with $412 Million in Trading Volume Following FDA Approval of Patisiran - AInvest
Is Alnylam Pharmaceuticals Inc. a good long term investmentHigh-profit capital plays - jammulinksnews.com
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - 富途牛牛
Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey
Lexicography: Clear And Unequivocal - The National Law Review
Lobbying Update: $390,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Truist Securities initiates Alnylam Pharmaceuticals stock with Buy rating By Investing.com - ca.investing.com
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Alnylam’s ELEVATE Study: A Closer Look at AHP Treatment and Market Impact - The Globe and Mail
Alnylam’s ALN-4324: A Promising Step in Obesity Treatment - TipRanks
Alnylam’s HELIOS-A Study: A Promising Update for hATTR Amyloidosis Treatment - TipRanks
Alnylam Pharmaceuticals stock price target raised to $290 by Cantor Fitzgerald - Investing.com Canada
Health Check: How Prudently Does Alnylam Pharmaceuticals (NASDAQ:ALNY) Use Debt? - Yahoo Finance
Alnylam's 2025 Earnings and Strategic Momentum: A Case for Biotech Leadership and Long-Term Value Creation - AInvest
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results - Business Wire
Alnylam’s ConTTRibute Study: A Closer Look at ATTR Amyloidosis Treatment - TipRanks
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 10 Analysts - Benzinga
Amvuttra gains UK approval for heart form of ATTR amyloidosis - The Pharma Letter
JPMorgan raises Alnylam Pharmaceuticals stock price target on Amvuttra forecast - Investing.com Canada
Hemophilia Clinical Trials, Companies, Therapeutic - openPR.com
Alnylam Pharmaceuticals Trading Volume Surges to $289 Million Ranking 356th in Daily Volume - AInvest
Alnylam Pharma (ALNY) Receives a Buy from Citi - The Globe and Mail
Alnylam Pharmaceuticals Trading Volume Drops 41.67% to $199 Million Ranking 472nd - AInvest
Jefferies reiterates Buy rating on Alnylam Pharmaceuticals stock, citing strong Amvuttra sales - Investing.com Canada
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyFree Top Growth Stock Recommendations - beatles.ru
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
Alnylam Pharmaceuticals (ALNY) Target Price Raised by Citigroup | ALNY Stock News - GuruFocus
Alnylam (ALNY) Receives Price Target Boost from Citi | ALNY Stoc - GuruFocus
Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com
BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN
Alnylam Beats Acuitas Claim on Patents in Pfizer Shot Suit (1) - Bloomberg Law News
Alnylam's Norton site is 'springboard' for expanding manufacturing capacity - The Business Journals
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Option Exercise |
118.73 |
19,297 |
2,291,057 |
68,245 |
Greenstreet Yvonne | Chief Executive Officer |
May 30 '25 |
Sale |
304.39 |
31,640 |
9,630,902 |
48,948 |
Greenstreet Yvonne | Chief Executive Officer |
Jun 02 '25 |
Sale |
306.00 |
19,297 |
5,904,882 |
48,948 |
자본화:
|
볼륨(24시간):